Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

national pharmaceutical industries co, oman - diclofenac potassium - film-coated tablet - 50 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

national pharmaceutical industries co, oman - diclofenac potassium - film-coated tablet - 50 mg

Bahrain - English - الهيئة الوطنية لتنظيم المهن والخدمات الصحية، مملكة البحرين

bahrain pharmacy - diclofenac potassium - film coated tablet - 50

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

muscat pharmaceutical trading oman - 20's (10's blister x 2) - tablet - 50 mg/tab - musculoskeletal ,joint diseases-rheumatic diseases , gout

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

20's (10's blister x 2) -

United States - English - NLM (National Library of Medicine)

eon labs, inc. - ticlopidine hydrochloride (unii: a1l4914fmf) (ticlopidine - unii:om90zuw7m1) - ticlopidine hydrochloride 250 mg - ticlopidine hydrochloride tablets are indicated: - to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke. because ticlopidine is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (ttp), neutropenia/agranulocytosis and aplastic anemia (see box warning  and warnings ), ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy. - as adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation (see clinical trials ). the use of ticlopidine is contraindicated in the following conditions: - hypersensitivity to the drug - presence of hematopoietic disorders such as neutropenia and thrombocytopenia or a past history of either ttp or aplastic anemia - presence of a hemostatic disorder or active

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - clopidogrel hydrogen sulfate, quantity: 97.875 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: hydrogenated castor oil; hyprolose; colloidal anhydrous silica; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red; microcrystalline cellulose - for prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease. ,acute coronary syndrome: clopidogrel tablets is indicated in combination with aspirin for patients with: ,- unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel tablets is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularization (surgical or pci, with or without stent); ,- st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - clopidogrel hydrogen sulfate, quantity: 97.875 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: hydrogenated castor oil; colloidal anhydrous silica; hyprolose; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin; iron oxide red - for prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease. ,acute coronary syndrome: clopidogrel tablets is indicated in combination with aspirin for patients with: ,- unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel tablets is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularization (surgical or pci, with or without stent); ,- st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - clopidogrel hydrogen sulfate, quantity: 97.875 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: hyprolose; colloidal anhydrous silica; hydrogenated castor oil; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red; microcrystalline cellulose - for prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease. ,acute coronary syndrome: clopidogrel tablets is indicated in combination with aspirin for patients with: ,- unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel tablets is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularization (surgical or pci, with or without stent); ,- st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - clopidogrel hydrogen sulfate, quantity: 97.875 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: hyprolose; hydrogenated castor oil; colloidal anhydrous silica; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red; microcrystalline cellulose - for prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease. ,acute coronary syndrome: clopidogrel tablets is indicated in combination with aspirin for patients with: ,- unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel tablets is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularization (surgical or pci, with or without stent); ,- st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.